Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. |
| Authors: |
Klatte, T Ittenson, A Rohl, FW Ecke, M Allhoff, EP Bohm, M
|
| Citation: |
Klatte T, etal., Br J Cancer. 2006 Nov 6;95(9):1167-73. Epub 2006 Oct 10. |
| RGD ID: |
6907413 |
| Pubmed: |
PMID:17031403 (View Abstract at PubMed) |
| PMCID: |
PMC2360567 (View Article at PubMed Central) |
| DOI: |
DOI:10.1038/sj.bjc.6603391 (Journal Full-text) |
We conducted a non-randomised controlled phase II trial to investigate the role of preoperative administration of interleukin-2 (IL-2) in patients with renal cell carcinoma undergoing tumour nephrectomy. A total of 120 consecutive patients were allocated alternately to the two study groups: perioperative immunomodulation with IL-2 (IL-2 group; n=60) and perioperative immunomonitoring without immunomodulation (control group; n=60). Patients from the IL-2 group received four doses of 10 x 10(6) IU m(-2) twice daily subcutaneously a week before operation followed by a daily maintenance dose of 3 x 10(6) IU m(-2) subcutaneously until a day before the operation. Parameters of cellular and humoral immunity (leucocytes, T-cell markers CD3, CD4, and CD8, B-cell marker CD19, monocyte marker CD14, natural killer (NK) cell markers CD16, CD56, and CD57, activation markers CD6, CD25, CD28, and CD69, progenitor cell marker CD34, as well as IL-2, IL-6, IL-10, soluble IL-2 receptor, IL-1 receptor antagonist, transforming growth factor-beta1, and vascular endothelial growth factor) were measured in peripheral venous blood at various intervals. Interleukin-2-related toxicity was WHO grade 1 (24%), 2 (67%), and 3 (9%). In the postoperative period, T-cell markers, activation markers, and NK cell markers decreased, and IL-6 and IL-10 increased. However, all these alterations were significantly less accentuated in patients who had been pretreated with IL-2. Median follow-up was 40 months. Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04). A similar effect was found for progression-free survival. We conclude that IL-2 can be safely administered in the perioperative period and modulates immunological parameters. However, to validate the survival data, a larger randomised phase III trial is needed.
|
| Genes (Rattus norvegicus) |
 |
| Il1rn (interleukin 1 receptor antagonist) |
| Genes (Mus musculus) |
|
| Il1rn (interleukin 1 receptor antagonist) |
| Genes (Homo sapiens) |
|
| IL1RN (interleukin 1 receptor antagonist) |
|
|
|
